Lung Cancer Clinical Trials

Trials for someone you care about with lung cancer.

Cancer

Recruiting Drug Device Behavioral Older adults Healthy volunteers

117 trials · showing 30

Comparing Sotorasib with Pembrolizumab for non-small cell lung cancer (NSCLC)

Explore this study →

There are 2 groups in this study. Group A receives Sotorasib. Group B, the comparison group, receives Pembrolizumab.

Sites in Montreal, Halifax and 4 more cities

Phase 3
2 groups
Sites in Halifax, Toronto and 4 more cities
Recruiting

Official title: A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-Small Cell Lung Cancer (NSCLC) · Amgen

Comparing 5 approaches for EGFR-mutant non-small cell lung cancer

Explore this study →

There are 5 groups in this study. Groups A, B, C, D and E receive VRN110755.

One site, in Toronto

Phase 1
5 groups
One site, in Toronto
Recruiting

Official title: A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

EGFR-Mutant Non-Small Cell Lung Cancer · Voronoi, Inc

Comparing Exertional Oxygen with Education and Support for fibrotic interstitial lung disease

Explore this study →

There are 3 groups in this study. Group A receives no study treatment and is followed for comparison. Group B receives Exertional Oxygen. Group C receives Exertional Oxygen, together with one or more of: Education and Support.

One site, in Edmonton

Phase 2
3 groups
One site, in Edmonton
Recruiting

Official title: Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

Fibrotic Interstitial Lung Disease · University of Alberta

Get them matched to the best-fit trials

Answer a few questions and we'll find the closest matches for lung cancer.

Comparing 4 approaches for non-small cell lung cancer

Explore this study →

There are 4 groups in this study. Group A receives one or more of: Divarasib and Pembrolizumab. Group B receives one or more of: Divarasib, Pembrolizumab, Carboplatin, Cisplatin and Pemetrexed. Groups C and D receive Divarasib.

Sites in Montreal, Ottawa and 1 more city

Phase 1
4 groups
Sites in Ottawa, Toronto and 1 more city
Recruiting

Official title: A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

Non-Small Cell Lung Cancer · Hoffmann-La Roche

Comparing Divarasib with Pemetrexed for non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Divarasib and Pembrolizumab. Group B, the comparison group, receives Pembrolizumab, Pemetrexed, Carboplatin and Cisplatin.

Sites in Barrie, Brampton and 7 more cities

Phase 3
2 groups
Sites in Kelowna, Victoria and 7 more cities
Recruiting

Official title: A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer · Hoffmann-La Roche

Testing Scheduling of the time of pembrolizumab for metastatic non small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Scheduling of the time of pembrolizumab infusions. Group B, the comparison group, receives Scheduling of the time of pembrolizumab infusions.

One site, in Edmonton

Phase 2
2 groups
One site, in Edmonton
Recruiting

Official title: This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

Metastatic Non Small Cell Lung Cancer · AHS Cancer Control Alberta

Comparing Pumitamig with Durvalumab for non-small cell lung cancer (NSCLC)

Explore this study →

There are 2 groups in this study. Group A receives Pumitamig. Group B, the comparison group, receives Durvalumab.

Sites in Montreal, Ottawa and 1 more city

Phase 3
2 groups
Sites in Ottawa, Montreal and 1 more city
Recruiting

Official title: A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Non-small Cell Lung Cancer (NSCLC) · Bristol-Myers Squibb

Testing LY3537982 against a placebo for non-small-cell lung carcinoma

Explore this study →

There are 8 groups in this study. Groups A, B, D and H receive LY3537982 and Pembrolizumab. Groups C and F receive LY3537982, Pembrolizumab and Pemetrexed, together with one or more of: Cisplatin and Carboplatin. Group E, the placebo group, receives Placebo and Pembrolizumab. …and 1 more groups.

Sites in Abbotsford British Columbia, Chicoutimi and 1 more city

Phase 3
8 groups
Sites in Abbotsford British Columbia, Chicoutimi and 1 more city
Recruiting

Official title: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company

Comparing Sevabertinib with Pembrolizumab for HER2 mutation advanced non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Sevabertinib. Group B, the comparison group, receives one or more of: Pembrolizumab, Cisplatin, Carboplatin and Pemetrexed.

Sites in Brampton, Montreal and 2 more cities

Phase 3
2 groups
Sites in Vancouver, Brampton and 2 more cities
Recruiting

Official title: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Non-small Cell Lung Cancer, HER2 Mutation · Bayer

Comparing 3 approaches for NSCLC (advanced non-small cell lung cancer)

Explore this study →

There are 3 groups in this study. Groups A and C receive BH-30643. Group B receives BH-30643 combo therapy with Carboplatin/Pemetrexed.

Sites in Edmonton and Toronto

Phase 1
3 groups
Sites in Edmonton and Toronto
Recruiting

Official title: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

NSCLC (Advanced Non-small Cell Lung Cancer) · BlossomHill Therapeutics

Testing Dose-escalated adaptive radiotherapy with Chemotherapy for small cell lung cancer

Explore this study →

Everyone in this study is in one group, which receives one or more of: Dose-escalated adaptive radiotherapy and Chemotherapy.

One site, in Edmonton

Phase 2
1 group
One site, in Edmonton
Recruiting

Official title: Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer

Small Cell Lung Cancer · AHS Cancer Control Alberta

Comparing Sacituzumab tirumotecan with Pembrolizumab for non-small cell lung cancer (NSCLC)

Explore this study →

There are 2 groups in this study. Group A receives Pembrolizumab and Sacituzumab tirumotecan, together with one or more of: Supportive care measures. Group B, the comparison group, receives Pembrolizumab, together with one or more of: Supportive care measures.

Sites in Brampton, Mississauga and 1 more city

Phase 3
2 groups
Sites in Brampton, Mississauga and 1 more city
Recruiting

Official title: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC) · Merck Sharp & Dohme LLC

Comparing Amivantamab with Olomorasib for non-small-cell lung carcinoma

Explore this study →

There are 2 groups in this study. Groups A and B receive one or more of: Amivantamab and Olomorasib.

One site, in Toronto

Phase 1
2 groups
One site, in Toronto
Recruiting

Official title: A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung · Janssen Research & Development, LLC

Comparing Lazertinib with Carboplatin for non-small-cell lung carcinoma

Explore this study →

There are 2 groups in this study. Group A receives Amivantamab and Lazertinib. Group B receives Amivantamab, Carboplatin and Pemetrexed.

One site, in Toronto

Phase 2
2 groups
One site, in Toronto
Recruiting

Official title: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC

Carcinoma, Non-Small-Cell Lung · Janssen Research & Development, LLC

Comparing 4 approaches for NSCLC stage IV

Explore this study →

There are 4 groups in this study. Group A receives one or more of: N-803, Tislelizumab and Docetaxel. Groups B and D, the comparison group, receive Docetaxel. Group C receives one or more of: N-803, Docetaxel and Prior failed checkpoint inhibitor.

Sites in Brampton, Kitchener and 5 more cities

Phase 3
4 groups
Sites in North Vancouver, Saint John and 5 more cities
Recruiting

Official title: Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

NSCLC Stage IV · ImmunityBio, Inc.

Comparing Firmonertinib with EGFR-TKI inhibitor based on for non-small-cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Firmonertinib. Group B, the comparison group, receives EGFR-TKI inhibitor based on investigator's choice.

Sites in Toronto, Brampton and 4 more cities

Phase 3
2 groups
Sites in Calgary, Edmonton and 4 more cities
Recruiting

Official title: Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

Non-Small-Cell Lung Cancer · ArriVent BioPharma, Inc.

Comparing Zongertinib with Pembrolizumab for non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Zongertinib. Group B, the comparison group, receives one or more of: Pembrolizumab, Atezolizumab, Durvalumab and Nivolumab.

Sites in Edmonton and Toronto

Phase 3
2 groups
Sites in Edmonton and Toronto
Recruiting

Official title: Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Non-small Cell Lung Cancer · Boehringer Ingelheim

Comparing Calderasib with MK-3475A for non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Calderasib and MK-3475A. Group B, the comparison group, receives Placebo and MK-3475A.

Sites in Chicoutimi, Moncton and 1 more city

Phase 3
2 groups
Sites in Moncton, Chicoutimi and 1 more city
Recruiting

Official title: MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

Non-small Cell Lung Cancer · Merck Sharp & Dohme LLC

Testing Tozorakimab against a placebo for viral lung infection and acute respiratory failure

Explore this study →

There are 2 groups in this study. Group A receives Tozorakimab. Group B, the placebo group, receives Placebo.

Sites in Montreal, Winnipeg and 8 more cities

Phase 3
2 groups
Sites in Calgary, New Westminster and 8 more cities
Recruiting

Official title: Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Viral Lung Infection and Acute Respiratory Failure · AstraZeneca

Comparing 5 approaches for advanced non-small cell lung cancer

Explore this study →

There are 5 groups in this study. Groups A, B, C and D receive Adagrasib. Group E, the comparison group, receives Pembrolizumab.

Sites in Edmonton, London and 4 more cities

Phase 2
5 groups
Sites in Edmonton, Vancouver and 4 more cities
Recruiting

Official title: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer · Mirati Therapeutics Inc.

Comparing Intismeran autogene with Pembrolizumab for non-small-cell lung carcinoma

Explore this study →

There are 2 groups in this study. Group A receives Pembrolizumab and Intismeran autogene, together with one or more of: Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Paclitaxel. Group B, the comparison group, receives Pembrolizumab and Placebo, together with one or more of: Cisplatin, Carboplatin, Pemetrexed, Gemcitabine and Paclitaxel.

Sites in Halifax, Hamilton and 5 more cities

Phase 3
2 groups
Sites in Halifax, Hamilton and 5 more cities
Recruiting

Official title: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Carcinoma, Non-Small-Cell Lung · Merck Sharp & Dohme LLC

Testing Intismeran against a placebo for non-small cell lung cancer

Explore this study →

There are 3 groups in this study. Group A receives Intismeran, together with one or more of: Pembrolizumab coformulated with berahyaluronidase alfa. Group B receives Intismeran. Group C, the placebo group, receives Placebo.

Sites in Hamilton, Kingston and 2 more cities

Phase 3
3 groups
Sites in Hamilton, Kingston and 2 more cities
Recruiting

Official title: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

Non-small Cell Lung Cancer · Merck Sharp & Dohme LLC

Comparing 11 approaches for non-small-cell lung carcinoma

Explore this study →

There are 11 groups in this study. Group A receives Pembrolizumab, Vibostolimab, Carboplatin and Paclitaxel. Group B receives Pembrolizumab, Vibostolimab, Carboplatin and Pemetrexed. Group C receives Pembrolizumab, Boserolimab, Carboplatin and Paclitaxel. …and 7 more groups.

One site, in Edmonton

Phase 1
11 groups
One site, in Edmonton
Recruiting

Official title: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Carcinoma, Non-Small-Cell Lung · Merck Sharp & Dohme LLC

Comparing Telisotuzumab Vedotin with Docetaxel for non small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Telisotuzumab Vedotin. Group B, the comparison group, receives Docetaxel.

Sites in Brampton, Edmonton and 3 more cities

Phase 3
2 groups
Sites in Edmonton, Brampton and 3 more cities
Recruiting

Official title: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer · AbbVie

Comparing sac-TMT with Pembrolizumab for non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives Pembrolizumab and sac-TMT, together with one or more of: Carboplatin, Paclitaxel and Nab-paclitaxel. Group B, the comparison group, receives Pembrolizumab, together with one or more of: Carboplatin, Paclitaxel and Nab-paclitaxel.

Sites in Montreal, Kingston and 2 more cities

Phase 3
2 groups
Sites in Kingston, Kitchener and 2 more cities
Recruiting

Official title: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Non-small Cell Lung Cancer · Merck Sharp & Dohme LLC

Comparing Rilvegostomig with Pembrolizumab for non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Rilvegostomig, Carboplatin, Paclitaxel and Nab-paclitaxel. Group B, the comparison group, receives one or more of: Pembrolizumab, Carboplatin, Paclitaxel and Nab-paclitaxel.

Sites in Montreal, Greater Sudbury and 4 more cities

Phase 3
2 groups
Sites in Saint John, Sydney and 4 more cities
Recruiting

Official title: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer · AstraZeneca

Testing Nerandomilast against a placebo for interstitial lung diseases

Explore this study →

There are 2 groups in this study. Group A receives Nerandomilast. Group B, the placebo group, receives Placebo matching nerandomilast.

Sites in Kelowna, Québec and 4 more cities

Phase 3
2 groups
Sites in Sherwood Park, Kelowna and 4 more cities
Recruiting

Official title: FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

Interstitial Lung Diseases · Boehringer Ingelheim

Comparing 3 approaches for non-small cell lung cancer

Explore this study →

There are 3 groups in this study. Group A receives Datopotamab Deruxtecan and Rilvegostomig. Group B receives Rilvegostomig. Group C, the comparison group, receives Pembrolizumab.

Sites in Montreal, Chicoutimi and 11 more cities

Phase 3
3 groups
Sites in Vancouver, Winnipeg and 11 more cities
Recruiting

Official title: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Non-Small Cell Lung Cancer · AstraZeneca

Comparing Rilvegostomig with Pembrolizumab for non-squamous non-small cell lung cancer

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Rilvegostomig, Carboplatin, Cisplatin and Pemetrexed. Group B, the comparison group, receives one or more of: Pembrolizumab, Carboplatin, Cisplatin and Pemetrexed.

Sites in Montreal, Abbotsford British Columbia and 7 more cities

Phase 3
2 groups
Sites in Abbotsford British Columbia, Saint John and 7 more cities
Recruiting

Official title: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

Non-squamous Non-small Cell Lung Cancer · AstraZeneca

Comparing obrixtamig with atezolizumab for small cell lung cancer (SCLC)

Explore this study →

There are 2 groups in this study. Group A receives obrixtamig, atezolizumab, carboplatin and etoposide. Group B receives atezolizumab, carboplatin and etoposide.

Sites in London and Sault Ste. Marie

Phase 3
2 groups
Sites in London and Sault Ste. Marie
Recruiting

Official title: DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Small Cell Lung Cancer (SCLC) · Boehringer Ingelheim

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Lung Cancer trials near you.

← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.